These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22675706)

  • 1. Contrast-enhanced ultrasonography for evaluating antiangiogenic treatment in hepatocellular carcinoma. A long way from research to clinical practice.
    Spârchez Z
    Med Ultrason; 2012 Jun; 14(2):85-6. PubMed ID: 22675706
    [No Abstract]   [Full Text] [Related]  

  • 2. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
    Moschouris H; Malagari K; Gkoutzios P; Kalokairinou M; Stamatiou K; Chatzimichail K; Kornezos I; Karagiannis E; Kiltenis M; Papadaki MG
    Med Ultrason; 2012 Jun; 14(2):87-94. PubMed ID: 22675707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
    Siemerink EJ; Mulder NH; Brouwers AH; Hospers GA
    Oncologist; 2008 Jun; 13(6):734-5; author reply 736-7. PubMed ID: 18586929
    [No Abstract]   [Full Text] [Related]  

  • 4. Major achievements in hepatocellular carcinoma.
    Bruix J; Llovet JM
    Lancet; 2009 Feb; 373(9664):614-6. PubMed ID: 19231618
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
    Maksimovic O; Schraml C; Hartmann JT; Bitzer M; Claussen CD; Pintoffl J; Horger M
    AJR Am J Roentgenol; 2010 Jan; 194(1):5-14. PubMed ID: 20028898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma: sorafenib before liver transplantation?
    Braillon A
    Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib in advanced hepatocellular carcinoma.
    Palmer DH
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib for HCC: a pragmatic perspective.
    Razumilava N; Gores GJ
    Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib in advanced hepatocellular carcinoma.
    Copur MS
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065701
    [No Abstract]   [Full Text] [Related]  

  • 11. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
    Greten TF; Manns MP; Malek N
    Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 13. Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
    Abou-Alfa GK
    Oncologist; 2009 Jan; 14(1):92-4. PubMed ID: 19144679
    [No Abstract]   [Full Text] [Related]  

  • 14. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
    Burak KW
    Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
    [No Abstract]   [Full Text] [Related]  

  • 15. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
    Zhu AX; Clark JW
    Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
    [No Abstract]   [Full Text] [Related]  

  • 16. Health-related quality of life and sorafenib.
    Spinzi G; Terreni N
    Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
    [No Abstract]   [Full Text] [Related]  

  • 17. Hepatocellular carcinoma: The beginning of a long journey.
    Cascinu S
    Dig Liver Dis; 2009 Oct; 41(10):707-8. PubMed ID: 19699696
    [No Abstract]   [Full Text] [Related]  

  • 18. Sorafenib in liver cancer--just the beginning.
    Roberts LR
    N Engl J Med; 2008 Jul; 359(4):420-2. PubMed ID: 18650519
    [No Abstract]   [Full Text] [Related]  

  • 19. Sorafenib in advanced hepatocellular carcinoma.
    Spinzi G; Paggi S
    N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
    [No Abstract]   [Full Text] [Related]  

  • 20. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.